Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Seres Theraptc (MCRB)

Seres Theraptc (MCRB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 294,046
  • Shares Outstanding, K 70,011
  • Annual Sales, $ 28,270 K
  • Annual Income, $ -98,940 K
  • 60-Month Beta 1.83
  • Price/Sales 10.80
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.26
  • Number of Estimates 4
  • High Estimate -0.22
  • Low Estimate -0.30
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.42 +22.89%
on 12/06/19
4.53 -7.28%
on 12/12/19
+0.51 (+13.82%)
since 11/13/19
3-Month
2.87 +46.34%
on 10/09/19
4.53 -7.28%
on 12/12/19
+0.41 (+10.82%)
since 09/13/19
52-Week
2.02 +107.92%
on 06/14/19
8.39 -49.94%
on 03/11/19
-2.49 (-37.22%)
since 12/13/18

Most Recent Stories

More News
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that...

AXLA : 3.48 (-1.97%)
DNLI : 18.90 (+0.91%)
EVLO : 4.38 (-1.13%)
KLDO : 5.94 (+0.17%)
MRNA : 18.62 (+0.92%)
RUBY : 13.11 (+1.24%)
MCRB : 4.20 (-3.67%)
SYRS : 4.59 (-0.65%)
Human Microbiome World Markets to 2023, Featuring Chr. Hansen, Enterome Bioscience, Seres Therapeutics, and Viome

The "Growth Opportunities in Human Microbiome Market, Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

MCRB : 4.20 (-3.67%)
Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19 at 9:10 a.m. ET.

MCRB : 4.20 (-3.67%)
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development...

NVS : 92.99 (-0.08%)
AXLA : 3.48 (-1.97%)
DNLI : 18.90 (+0.91%)
EVLO : 4.38 (-1.13%)
KLDO : 5.94 (+0.17%)
MRNA : 18.62 (+0.92%)
RUBY : 13.11 (+1.24%)
MCRB : 4.20 (-3.67%)
SYRS : 4.59 (-0.65%)
Seres Therapeutics (MCRB) Reports Q3 Loss, Tops Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 11.54% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

MCRB : 4.20 (-3.67%)
Seres Therapeutics: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Seres Therapeutics Inc. (MCRB) on Tuesday reported a loss of $16.4 million in its third quarter.

MCRB : 4.20 (-3.67%)
Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update

--- Debt facility secured, providing up to $50 million in additional capital; Corporate resources are expected to support operations into Q2 2021 -

MCRB : 4.20 (-3.67%)
Seres Therapeutics to Host Third Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on November 5, 2019

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on November 5, 2019 at 8:30 a.m. ET to discuss third quarter 2019 results and...

MCRB : 4.20 (-3.67%)
United States Fecal Microbiome Transplant Market Forecasts to 2025, Featuring OpenBiome, Maat Pharma, Finch Therapeutics, Rebiotix, Seres Therapeutics, and Vedanta Bioscience

The "US Fecal Microbiome Transplant Market Outlook 2025" report has been added to ResearchAndMarkets.com's offering.

MCRB : 4.20 (-3.67%)
Seres Therapeutics, Inc. (MCRB) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Seres Therapeutics, Inc. (MCRB).

MCRB : 4.20 (-3.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade MCRB with:

Business Summary

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 4.64
1st Resistance Point 4.42
Last Price 4.20
1st Support Level 4.04
2nd Support Level 3.88

See More

52-Week High 8.39
Fibonacci 61.8% 5.96
Fibonacci 50% 5.20
Fibonacci 38.2% 4.45
Last Price 4.20
52-Week Low 2.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar